文献速递中医儿科中药与中成药合理使用

蒲地蓝消炎口服液治疗儿童流行性腮腺炎的疗效评价与机制预测

Clinical efficacy evaluation and potential mechanism prediction on Pudilan Xiaoyan oral liquid in treatment of mumps in children based on meta-analysis, network pharmacology, and molecular docking.
PubMed 文献 · Front Pharmacol · 2022-09-23

该研究采用Meta分析结合网络药理学与分子对接,评估蒲地蓝消炎口服液(PDL)联合抗病毒药物治疗儿童流行性腮腺炎的疗效与安全性。共纳入12项随机对照试验(N=1,307),结果显示联合治疗可提高有效率(OR=5.94),缩短发热、头痛、腮腺肿胀、腮腺疼痛及食欲减退的持续时间,且不良反应较少。网络药理学筛选出11个核心成分和7个核心靶点,涉及细胞因子-细胞因子受体相互作用及Th17细胞分化等通路。

要点

  • PDL联合抗病毒药物可提高儿童流行性腮腺炎治疗有效率(OR=5.94)。
  • 联合治疗可缩短发热、头痛、腮腺肿胀、腮腺疼痛和食欲减退的持续时间。
  • PDL可能通过多成分、多靶点、多通路发挥抗炎和抗病毒作用。

核心结论

  • PDL联合抗病毒药物可有效提高儿童流行性腮腺炎疗效并快速缓解相关症状。
  • 其疗效可能与PDL多成分、多靶点、多通路的抗炎和抗病毒机制有关。
  • 上述结果需进一步研究证实。

研究设计与样本

  • 系统检索CNKI、万方、维普、Sinomed、中国医学期刊全文数据库、PubMed、Embase、Cochrane Library、Web of Science和Google Scholar,截至2022年3月3日。
  • 纳入比较PDL联合抗病毒药物与单用抗病毒药物的随机对照试验,中英文文献。
  • 共纳入12项研究,N=1,307例参与者。
  • 采用固定效应或随机效应模型合并数据,Stata 15软件计算OR或SMD及95%CI。
  • 网络药理学收集PDL活性成分与腮腺炎靶点,构建药物-成分-靶点网络和蛋白互作网络,进行GO和KEGG分析及分子对接。

主要发现

  • 与单用抗病毒药物相比,PDL联合抗病毒药物有效率更高(OR=5.94)。
  • 联合治疗缩短发热持续时间(SMD=-1.05)、头痛(SMD=-0.69)、腮腺肿胀(SMD=-1.30)、腮腺疼痛(SMD=-2.53)和食欲减退(SMD=-0.56)。
  • 联合治疗报告的不良反应较少。
  • 从PDL的113个活性成分和57个腮腺炎靶点中筛选出11个核心成分(如槲皮素、异槲皮素)和7个核心靶点(如ALB、IL-6)。
  • 富集通路包括细胞因子-细胞因子受体相互作用和Th17细胞分化。

关键数值与推荐

  • 有效率:OR=5.94(PDL联合抗病毒药物 vs. 单用抗病毒药物)。
  • 发热持续时间:SMD=-1.05(95%CI未报告)。
  • 头痛持续时间:SMD=-0.69(95%CI未报告)。
  • 腮腺肿胀持续时间:SMD=-1.30(95%CI未报告)。
  • 腮腺疼痛持续时间:SMD=-2.53(95%CI未报告)。

临床怎么用

  • 对于儿童流行性腮腺炎,可考虑在抗病毒治疗基础上联合PDL以提升疗效并加速症状缓解。
  • 联合用药可能减少不良反应,但需结合患儿具体情况评估。
  • PDL的多成分-多靶点作用机制为临床使用提供了理论依据,但需进一步验证。

局限性

  • 研究结果需进一步研究证实。
  • 原文未报告纳入试验的偏倚风险、异质性及95%CI具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Mumps is caused by the mumps virus and is characterized by pain and parotid gland swelling. Although its incidence has declined due to vaccines, outbreaks still occur among children. In addition, it can lead to severe complications, so it has a certain perniciousness. Pudilan Xiaoyan oral liquid (PDL), a Chinese patent medicine, commonly treats children with mumps. However, its safety, efficacy, and specific mechanisms lack relevant evaluation and analysis. Therefore, we did a meta-analysis of the randomized controlled trials combined with a network pharmacology analysis to assess the efficacy and safety of PDL in relieving symptoms of mumps in children and investigate its pharmacological mechanisms. Methods: This study systematically searched the China National Knowledge Infrastructure (CNKI), WanFang Data Knowledge Service Platform, VIP Database, Sinomed, Chinese Medical Journal Full-text Database, PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar for the published randomized controlled trials (date up to 3 March 2022; studies in both English and Chinese) comparing PDL and antiviral drug combination treatment to standalone antiviral drug treatment. The primary outcomes in this study were the effective rate and duration of five characteristic symptoms of children's mumps. We assessed the pooled data by using a fix-effect or random-effect model. We illustrated an odds ratio (OR) or standardized mean difference (SMD) with a 95% confidence interval (CI) using the Stata 15 software. In network pharmacology, active components of PDL were collected from the traditional Chinese medicine system pharmacology technology platform and the CNKI studies, while mumps' targets were collected from databases of the Genecards and Online Mendelian Inheritance in Man (OMIM), and then we constructed a "drug-component-target" network and a protein-protein interaction network using Cytoscape 3.9.0 for screening the core components and targets. Next, we ran Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of intersection targets of PDL and mumps. Finally, molecular docking was performed between core components and targets. Results: Of 70 identified studies, 12 were eligible and included in our analysis (N = 1,307 participants). Compared with the antiviral drug treatments, combination treatment using PDL and antiviral drugs provided higher effective rates (OR = 5.94), shorter symptom durations for fever (SMD = -1.05), headache (SMD = -0.69), parotid gland swelling (SMD = -1.30), parotid gland pain (SMD = -2.53), and loss of appetite (SMD = -0.56) with fewer reported side effects. Of the 113 active components of PDL and 57 mumps' targets, 11 core components like quercetin, isoetin, and seven core targets such as albumin (ALB) and interleukin-6 were obtained. Moreover, the potential pathways identified included cytokine-cytokine receptor interaction and T helper cell 17 (Th17 cell) differentiation. Molecular docking results revealed that most core components and targets could form stable structures. The core components, including isoetin, quercetin, and luteolin, and core targets involving heat shock protein HSP 90-alpha (HSP90AA1), estrogen receptor (ESR1), and ALB showed the best affinities. Conclusion: The combined use of PDL and antiviral drugs could effectively improve the efficacy of mumps among children and rapidly alleviate mumps-related symptoms. This efficacy may be associated with the anti-inflammatory and antiviral mechanisms by which PDL acts using multiple components, multiple targets, and multiple pathways. However, these results should be confirmed by further studies.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Cui X, Xi J, et al. Clinical efficacy evaluation and potential mechanism prediction on Pudilan Xiaoyan oral liquid in treatment of mumps in children based on meta-analysis, network pharmacology, and molecular docking. Front Pharmacol. 2022. PMID: 36210814. doi:10.3389/fphar.2022.956219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。